Dr. Micheal Digiovanna D.O., C.P.I. ; Lianna McCcord, MPS, PA-C
Diabetes is a foremost non-communicable disease affecting a significant percentage of the world's population, responsible for increasing rates of patients' morbidity and mortality. Conventionally, medical practitioners and scientists have grouped the disease into three types: diabetes mellitus (Type 1/T1DM), diabetes mellitus (Type 2/T2DM), and gestational diabetes (GD). Despite its different types, this research proposal critically investigates the potential use of stem cells as an alternative cure for T1DM. T1DM refers to an autoimmune condition that affects the ability of insulin production cells located in the pancreas. Typically,
T1DM occurs when an individual's pancreatic β-cell mass reduces by 70-80%. T1DM is a prevalent autoimmune disorder that destroys the body’s
immunological beta cells. Over the years, insulin has typically been the mainstay of therapy.
Nonetheless, advances in the microencapsulation of islet cells and pancreatic transplantation have become popular. Even so, innovative stem cell therapy procedures provide T1DM treatment options through cellular transplantation.
Although these options are far from perfect, the opportunity to use embryonic or adult stem cells has the potential to address future T1DM treatment demands.
However, stem cell therapy presents considerable challenges.
"COULD CELLS THERAPY THE ALTERNATE CURE FOR T1DM AS COMPARED TO ISLET / STEM PANCREATIC TRANSPLANTATION?,"
Lynchburg Journal of Medical Science: Vol. 2
, Article 27.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol2/iss2/27
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.